Asset profile

Interferon alfa-2b (Intron A)

Unknown / undisclosed

Preview Research free. Sign in to unlock 3 full asset or company pages every day, no card needed.Sign in to unlock this page
Approvedregulatory verdict

Evidence outlook

Approved: Chronic Hepatitis B

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

Competitive landscape

46 competitors in this universe: 2 direct rivals (same mechanism and indication), 5 same-class, 39 same-indication.

Unlock with Research ↗
DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Interferon Alfa-2b (Intron A): this drugApproved—Type I interferon receptor
Peginterferon Alfa-2a (Pegasys)Approved—Type I interferon receptor
Human Serum Albumin / Interferon Alpha2b Fusion ProteinPhase 1/2Biologic (subtype unspecified)Type I interferon receptor
AnifrolumabApprovedMonoclonal antibodyType I interferon receptor, Type I interferon receptor subunit 1 (IFNAR1)
Interferon Beta-1bApprovedBiologic (subtype unspecified)Interferon beta receptor (type I IFN signaling), Type I interferon receptor
Interferon-Beta1ApprovedBiologic (subtype unspecified)Type I interferon receptor
Peginterferon Beta-1a (Plegridy)ApprovedBiologic (subtype unspecified)Type I interferon receptor, Interferon beta receptor (type I IFN signaling)
Rebif (interferon Beta 1a)ApprovedBiologic (subtype unspecified)Interferon beta receptor (type I IFN signaling), Type I interferon receptor
Adefovir Dipivoxil (Hepsera)ApprovedSmall molecule—
Entecavir (Baraclude)ApprovedSmall molecule—
Hepatitis B Immune Globulin (HepaGam B)ApprovedSmall molecule—
Lamivudine (Epivir-HBV)Approved——
Telbivudine (Tyzeka)Approved——
Tenofovir Alafenamide (Vemlidy)ApprovedSmall molecule—
Tenofovir Disoproxil Fumarate (Viread)ApprovedSmall moleculeHIV reverse transcriptase (RT)
Diluted I.V.-Hepabig inj(GC5103)Phase 3Biologic (subtype unspecified)—

…and 31 more. Research shows the complete landscape.

Research

Unlock the full comparison

Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.

Upcoming events

No upcoming readouts on record for this asset.

All registered studies

Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.

Phase 3 (3)
Phase 2/3 (1)
Phase 2 (1)
Phase 1/2 (2)
Phase 1 (7)
Phase 4 (4)
Used as active comparator (1)
Appears in other studies (1)